ARCHIVES

Predicant, Correlogic executives contradict scientists’ claim that firms didn’t appear to compete.

This article is from The Cancer Letter archive.

Vol. 30 No. 26 | June 25, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: FDA Deputy Commissioner Friedman Named Senior VP, Clinical Affairs, At G.D. Searle

June 16, 1999

Bailes: ASCO To Strengthen State Affiliates, Begin Quality Of Care Study, Talk With FDA.

May 26, 2000

House Members Express Support for Cancer Program

September 12, 1980

Analysis Reveals Patient Subset With Lower PFS in Phase III Trial

December 30, 2011

Funding Opportunities.

July 19, 2002

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

July 26, 2002